News Search Results
Jun 10, 2025, 11:30 ET Broadband Market Size to Reach USD 960.14 Billion by 2031, Driven by Experiences Significant Growth Owing to Growing Demand for High-Speed Internet and Global Internet Penetration | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Logo:
More news about: The Insight Partners
Jun 10, 2025, 11:01 ET Spark Detection System Market Size to Surpass $ 449.53 Million, Globally, by 2031 at 7.0% CAGR, Experiences Growth with the Rise in Adoption of Wood Panel Industry
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 10, 2025, 10:15 ET Exosome Research Market worth US$480.6 million by 2030 with 17.5% CAGR | MarketsandMarkets™
that foster an environment conducive to innovation and development. The region boasts a robust research infrastructure that supports cutting-edge biotechnology and pharmaceutical R&D. Significant financial investments from both private and public sectors have accelerated advancements in these fields,
More news about: MarketsandMarkets
Jun 10, 2025, 09:46 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jun 10, 2025, 09:03 ET The Chicago School Launches Online Master of Science Program in Biomedical Sciences
will prepare students for a variety of career paths, including DO or MD medical school, medical research, and careers in the pharmaceutical and biotechnology industries. "Many aspiring medical professionals face barriers to entry, whether due to gaps in their academic background or challenges balancing
More news about: The Chicago School
Jun 10, 2025, 09:01 ET Phenomix and Mayo Clinic Publish Research Demonstrating Utility of MyPhenome Test for Personalized GLP-1 and Phen-Top Treatment
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark study validating the utility of its
More news about: Phenomix Sciences
Jun 10, 2025, 09:00 ET Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program
BOSTON, June 10, 2025 /PRNewswire/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and treatment
More news about: Curadev Pharma
Jun 10, 2025, 09:00 ET Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation
10, 2025 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the recent release of its Nach01 foundation model on Amazon Web Services
More news about: Insilico Medicine
Jun 10, 2025, 09:00 ET Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress
Mass., June 10, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced a total of 11 presentations
More news about: Hemab Therapeutics
Jun 10, 2025, 08:59 ET Spiderwort Biotechnologies Inc. Receives Health Canada Investigational Testing Authorization for Next-Generation Dermal Filler
ON, June 10, 2025 /PRNewswire/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced it has received Investigational Testing Authorization (ITA) from Health
More news about: Spiderwort Biotechnologies Inc.
Jun 10, 2025, 08:58 ET X-Therma Welcomes Biotech Veteran Neil Warma to its Board of Directors
X-Therma Inc., a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, today announced the appointment of
More news about: X-Therma.com
Jun 10, 2025, 08:37 ET Nordic Capital to partner with Minerva Imaging, to support its growth journey in the radiopharmaceutical space
that combines scientific excellence with end-to-end service capabilities. The company partners with many of the world's leading pharmaceutical and biotechnology companies and is widely recognised for its industry-leading expertise and best-in-class capabilities. Today, Minerva employs over 150 highly skilled
More news about: Nordic Capital
Jun 10, 2025, 08:31 ET Nordic Capital to partner with Minerva Imaging, to support its growth journey in the radiopharmaceutical space
that combines scientific excellence with end-to-end service capabilities. The company partners with many of the world's leading pharmaceutical and biotechnology companies and is widely recognised for its industry-leading expertise and best-in-class capabilities. Today, Minerva employs over 150 highly skilled
More news about: Nordic Capital
Jun 10, 2025, 08:00 ET ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatment of cancer, announced that the first patient diagnosed
More news about: ImmVira
Jun 10, 2025, 07:50 ET ZINZINO AB (PUBL.): Zinzino acquires assets from Ecosystem for increased distribution power in France and DOM-TOM
another strategically important step in Zinzino's growth plans focused on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Ecosystem is a French direct selling company based in Paris
More news about: Zinzino
Jun 10, 2025, 07:40 ET OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected
More news about: EVERSANA
Jun 10, 2025, 07:30 ET Factor Bioscience to Unveil iMacrophages Engineered to Combat Solid Tumors at the ISSCR Annual Meeting
June 10, 2025 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced its participation
More news about: Factor Bioscience Inc.
Jun 10, 2025, 07:00 ET Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed
More news about: Anixa Biosciences, Inc.
Jun 10, 2025, 07:00 ET Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
first-in-class pan-mesenchymal cancer targeting ADC in phase 1/2 clinical development. About Adcendo Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.
More news about: Adcendo
Jun 10, 2025, 07:00 ET Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
first-in-class pan-mesenchymal cancer targeting ADC in phase 1/2 clinical development. About Adcendo Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.
More news about: Adcendo
Jun 10, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized
More news about: Bio-Techne Corporation
Jun 10, 2025, 06:00 ET Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs). The agreement, officially
More news about: Sanyou Bio
Jun 10, 2025, 06:00 ET Blue Water Acquisition Corp. III Announces the Upsized Pricing of $220 Million Initial Public Offering
business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the artificial intelligence (AI), biotechnology, healthcare and technology sectors. Forward-Looking Statements This press release contains statements that constitute "forward-looking
More news about: Blue Water Acquisition Corp iii
Jun 10, 2025, 04:49 ET Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
-- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Nuevocor
Jun 10, 2025, 04:15 ET Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
enhancing the overall treatment impact and long-term value." The BIO International Convention is the world's largest and most influential biotechnology event, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation
More news about: Caliway Biopharmaceuticals